Appetite regulation
Tirzepatide acts on pathways involved in hunger and satiety, which may reduce appetite and overall caloric intake.
$549.00 ~2 month supply 1 vial
A once-weekly prescription injection combining tirzepatide + B12 to support appetite control, weight management, glucose regulation, and metabolic health.
May support appetite control: Targets GLP-1 pathways involved in hunger and satiety.
May support weight management: Helps reduce appetite and caloric intake as part of a clinician-guided weight-management program.
May support glucose regulation: Helps regulate glucose-dependent insulin secretion and glucagon activity.
May support metabolic health: May improve multiple metabolic parameters alongside appropriate nutrition, activity, and clinical care.
Tirzepatide can cause gastrointestinal and other adverse effects and is not appropriate for every patient.
Tirzepatide carries a boxed warning regarding the risk of thyroid C-cell tumors observed in animal studies.
Tirzepatide should not be used in patients with:
Additional clinical considerations may include:
Tirzepatide delays gastric emptying and may affect the absorption of certain oral medications. Patients should review all prescription medications, over-the-counter medications, and supplements with their prescribing clinician.
Because compounded formulations may differ from FDA-approved tirzepatide products, patients should follow the exact concentration and dosing instructions provided with their prescription.
Common Side Effects
Commonly reported adverse effects associated with tirzepatide may include:
Gastrointestinal symptoms may be more noticeable during treatment initiation or following dose increases.
Tirzepatide acts on the GLP-1 receptor, but it also activates the GIP receptor. It is therefore commonly described as a dual GIP/GLP-1 receptor agonist.
This distinguishes it from medications such as semaglutide, which primarily target the GLP-1 receptor.
Tirzepatide affects hormonal pathways involved in appetite, satiety, glucose regulation, and food intake. Many patients experience reduced hunger and caloric intake, which can support weight reduction when combined with an appropriate nutrition, activity, and medical-care plan.
This compounded formulation contains methylcobalamin, an active form of vitamin B12. Vitamin B12 is an essential nutrient involved in normal neurological function, red blood cell formation, DNA synthesis, and cellular energy metabolism.
Its inclusion does not change tirzepatide’s primary mechanism of action.
Tirzepatide is generally administered once weekly by subcutaneous injection. The exact dose and titration schedule should follow the patient’s prescription.
Subcutaneous medications are typically injected into areas such as the abdomen, thigh, or upper arm. Patients should follow the injection-site and administration instructions provided by their clinician and dispensing pharmacy.
Appetite and glucose-related effects may occur relatively early in treatment, while weight changes generally develop progressively over time.
Individual response varies, and treatment should be evaluated over time by the prescribing clinician.
Not necessarily. Dose escalation depends on individual response, tolerability, and the prescribing clinician’s treatment plan.
Patients should not increase their dose simply because four weeks have passed unless instructed to do so.
For FDA-approved tirzepatide products, 15 mg once weekly is the maximum recommended maintenance dose. Compounded prescriptions should always be administered according to the individualized prescription and pharmacy label.
No. Both medications affect the GLP-1 receptor, but tirzepatide also activates the GIP receptor.
Semaglutide is a GLP-1 receptor agonist, while tirzepatide is a dual GIP/GLP-1 receptor agonist.
A compounded tirzepatide prescription may be provided through telehealth when a licensed clinician determines that treatment is medically appropriate and applicable prescribing and compounding requirements are satisfied.
Tirzepatide + B12 is a compounded prescription formulation combining tirzepatide with methylcobalamin, an active form of vitamin B12.
Tirzepatide activates both GIP and GLP-1 receptors and influences appetite, glucose regulation, and metabolic signaling.
All dosing should follow the instructions provided by the prescribing clinician.
Tirzepatide activates both GIP and GLP-1 receptors, two incretin hormone pathways involved in appetite, glucose regulation, and metabolic signaling.
Tirzepatide acts on pathways involved in hunger and satiety, which may reduce appetite and overall caloric intake.
Tirzepatide can increase insulin secretion when blood glucose is elevated, supporting post-meal and overall glucose regulation.
Tirzepatide can reduce inappropriate glucagon secretion, helping decrease excess glucose production by the liver.
Tirzepatide may slow gastric emptying, particularly following treatment initiation, which can contribute to increased satiety.
Together, the formulation combines the appetite and metabolic effects of tirzepatide with the nutritional and metabolic functions of vitamin B12.
Tirzepatide is an incretin-based medication that acts as both a GIP and GLP-1 receptor agonist.
FDA-approved tirzepatide products are indicated for specific uses, including type 2 diabetes and chronic weight management in eligible patients. Compounded Tirzepatide + B12 is a separate formulation and is not itself FDA-approved.
When clinically appropriate, a licensed clinician may prescribe a compounded tirzepatide formulation as part of an individualized treatment plan.
Treatment eligibility should be determined through an individualized medical evaluation.
All dosing should follow the instructions provided by the prescribing clinician.
Tirzepatide + B12 Injectable combines tirzepatide, a dual GIP and GLP-1 receptor agonist, with vitamin B12 to target pathways involved in glucose regulation, insulin responsiveness, appetite, and cellular metabolism. Tirzepatide may enhance glucose-dependent insulin secretion, modulate glucagon signaling, slow gastric emptying, and influence appetite and satiety pathways within the central nervous system. Vitamin B12 serves as an essential cofactor involved in red blood cell formation, DNA synthesis, neurologic function, and cellular energy metabolism.
